VIP: The Cause of the Watery Diarrhoea Syndrome

  • I. M. Modlin
  • S. R. Bloom
  • S. Mitchell
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 106)


Verner and Morrison in 1958 described a syndrome of refractory watery diarrhoea and hypokalaemia associated with non-insulin secreting tumours of the pancreatic islets. In the following years many such cases were reported and suggestions made as to the causative agent1. In fact at one time or another almost all the characterised GI hormones have been put forward as the cause of the watery diarrhoea syndrome. In 1973 it was reported that the responsible tumour contained large quantities of the newly discovered polypeptide VIP and that plasma VIP levels were extremely elevated. The relationship of VIP to the syndrome seemed likely because the biological actions of VIP closely fitted the described symptoms of the patients. Thus, VIP is a potent stimulant of small intestinal juice production and a powerful inhibitor of gastric acid secretion. It also increases the output of hepatic glucose, stimulates pancreatic bicarbonate secretion, relaxes the gall bladder and causes vasodilation2. These may explain the frequent clinical findings of hypochlorhydria, diabetes, flushing attacks, high resting pancreatic juice production and a flaccid distended gall bladder.


Vasoactive Intestinal Peptide Watery Diarrhoea Royal Postgraduate Medical School Selective Venous Sampling Pancreatic Bicarbonate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bloom SR, Polak JM, Pearse AGE: Vasoactive intestinal peptide and watery diarrhoea syndrome. Lancet, II, 14–16, 1973CrossRefGoogle Scholar
  2. 2.
    Bloom SR, Polak JM: The role of VIP in pancreatic cholera. Gastrointestinal Hormones, (ed) JC Thompson, Austin, University of Texas Press, 635–642, 1975Google Scholar
  3. 3.
    Bloom SR, Polak JM: VIP measurement in distinguishing Verner-Morrison syndrome and Pseudo Verner-Morrison syndrome. Clin Endocr. 5, 223s–228s, 1976PubMedCrossRefGoogle Scholar
  4. 4.
    Modlin IM, Bloom SR, Mitchell SJ: The role of VIP in diarrhoea. Gut, 18, A418, 1977Google Scholar
  5. 5.
    Mitchell SJ, Bloom SR, Modlin IM: VIP assay and intestinal ischaemia. (In Press)Google Scholar
  6. 6.
    Gagel RF, Costanza ME, Delellis RA, Norton RA, Bloom SR, Miller HH, Ucci A, Nathanson L: Streptozotocin-treated Verner-Morrison syndrome: plasma vasoactive intestinal peptide and tumour responses. Arch intern Med, 136, 1429–1435, 1976PubMedCrossRefGoogle Scholar
  7. 7.
    Fairclough PD, Bloom SR, Mitchell SJ: Plasma-VIP in ulcerative colitis. Lancet, I, 964, 1976CrossRefGoogle Scholar
  8. 8.
    Modlin IM, Bloom SR, Mitchell S: VIP release in intestinal ischaemia. Gut, (In Press) 1977Google Scholar
  9. 9.
    Schwartz CJ, Kimberg DV, Sheerinhe V, Field M, Said SI: Vaso-active intestinal peptide stimulation of adenolate cyclase and active electrolyte secretion in intestinal mucosa. J Clin’invest, 54, 536–544, 1974CrossRefGoogle Scholar
  10. 10.
    Klaeveman HL, Conlon TP, Levy AG, Gardner JD: Effect of gastrointestinal hormones on adenylate cyclose activity in human jejunal mucosa. Gastroenterology, 68, 667–675, 1975PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • I. M. Modlin
    • 1
  • S. R. Bloom
    • 1
  • S. Mitchell
    • 1
  1. 1.Departments of Surgery and MedicineRoyal Postgraduate Medical SchoolLondonUK

Personalised recommendations